These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

875 related articles for article (PubMed ID: 32394185)

  • 21. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
    Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
    Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
    Sheikh S; Kuruvilla J
    Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
    [No Abstract]   [Full Text] [Related]  

  • 25. Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
    Ferreira CR; Manohar V; Zhao S; Bangs CD; Cherry A; Azevedo RS; Lage LAPC; Pereira J; Zerbini MCN; Gratzinger D; Natkunam Y
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):10-16. PubMed ID: 31809310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.
    Sun J; Zheng Y; Mamun M; Li X; Chen X; Gao Y
    Biomed Pharmacother; 2020 Sep; 129():110504. PubMed ID: 32768978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Where does PD-1 blockade fit in HL therapy?
    Herrera AF
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
    Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
    Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
    Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
    Liu Y; Huang R; Liu L; Meng Y; Liu X
    Cell Biochem Funct; 2020 Apr; 38(3):242-248. PubMed ID: 31709594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.
    Shen J; Li S; Medeiros LJ; Lin P; Wang SA; Tang G; Yin CC; You MJ; Khoury JD; Iyer SP; Miranda RN; Xu J
    Mod Pathol; 2020 Mar; 33(3):324-333. PubMed ID: 31383967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
    Pascual M; Mena-Varas M; Robles EF; Garcia-Barchino MJ; Panizo C; Hervas-Stubbs S; Alignani D; Sagardoy A; Martinez-Ferrandis JI; Bunting KL; Meier S; Sagaert X; Bagnara D; Guruceaga E; Blanco O; Celay J; Martínez-Baztan A; Casares N; Lasarte JJ; MacCarthy T; Melnick A; Martinez-Climent JA; Roa S
    Blood; 2019 May; 133(22):2401-2412. PubMed ID: 30975638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
    Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
    Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.
    Juárez-Salcedo LM; Sandoval-Sus J; Sokol L; Chavez JC; Dalia S
    Crit Rev Oncol Hematol; 2017 May; 113():52-62. PubMed ID: 28427522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
    Armand P; Shipp MA; Ribrag V; Michot JM; Zinzani PL; Kuruvilla J; Snyder ES; Ricart AD; Balakumaran A; Rose S; Moskowitz CH
    J Clin Oncol; 2016 Nov; 34(31):3733-3739. PubMed ID: 27354476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.